Información:
Error:
ID
13707
Descripción
Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia; ODM derived from: https://clinicaltrials.gov/show/NCT00703820
Link
https://clinicaltrials.gov/show/NCT00703820
Palabras clave
Versiones (1)
- 29/2/16 29/2/16 -
Titular de derechos de autor
CC BY-NC 3.0
Subido en
29 de febrero de 2016
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY-NC 3.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Eligibility Acute Myeloid Leukemia NCT00703820
Eligibility Acute Myeloid Leukemia NCT00703820
- StudyEvent: Eligibility
Similar models
Eligibility Acute Myeloid Leukemia NCT00703820
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
age
Item
age less than or equal to 21 years at time of study entry.
boolean
C0001779 (UMLS CUI [1])
prior therapy
Item
no prior therapy for this malignancy except for one dose of intrathecal therapy and the use of hydroxyurea or low-dose cytarabine (100-200 mg/m2 per day for one week or less ) for hyperleukocytosis.
boolean
C1514463 (UMLS CUI [1])
written informed consent
Item
written informed consent according to institutional guidelines
boolean
C0021430 (UMLS CUI [1])
pregnancy test
Item
female patients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to enrollment
boolean
C0032976 (UMLS CUI [1])
contraception
Item
male and female participants must use an effective contraceptive method during the study and for a minimum of 6 months after study treatment.
boolean
C0700589 (UMLS CUI [1])
down syndrome
Item
down syndrome
boolean
C0013080 (UMLS CUI [1])
apl
Item
acute promyelocytic leukemia (apl)
boolean
C0023487 (UMLS CUI [1])
juvenile myelomonocytic leukemia
Item
juvenile myelomonocytic leukemia (jmml)
boolean
C0349639 (UMLS CUI [1])
fanconi anemia
Item
fanconi anemia (fa)
boolean
C0015625 (UMLS CUI [1])
kostmann syndrome
Item
kostmann syndrome
boolean
C1853118 (UMLS CUI [1])
shwachman syndrome
Item
shwachman syndrome
boolean
C0272170 (UMLS CUI [1])
bone marrow failure syndromes
Item
other bone marrow failure syndromes
boolean
C2931245 (UMLS CUI [1])
use of concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocol.
Item
use of concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocol.
boolean
C0392920 (UMLS CUI [1])
C1522449 (UMLS CUI [2])
C1531518 (UMLS CUI [3])
C1522449 (UMLS CUI [2])
C1531518 (UMLS CUI [3])
use of investigational agents
Item
use of investigational agents within 30 days or any anticancer therapy within 2 weeks before study entry with the exception of it therapy, hydroxyurea, or low-dose cytarabine as stated above. the patient must have recovered from all acute toxicities from any previous therapy.
boolean
C1875319 (UMLS CUI [1])
systemic infection
Item
systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment).
boolean
C0009488 (UMLS CUI [1])
pregnancy or lactation
Item
pregnant or lactating patients.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0006147 (UMLS CUI [2])
comorbidity interfering with study protocol
Item
any significant concurrent disease, illness, or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results.
boolean
C1321605 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])